ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Eupraxia Pharmaceuticals Inc

Eupraxia Pharmaceuticals Inc (EPRX)

4,41
0,01
(0,23%)
Fermé 08 Décembre 10:12PM

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
4,41
Prix Achat
4,40
Prix Vente
4,44
Volume échangé
5 147
4,41 Fourchette du Jour 4,49
3,07 Plage de 52 semaines 7,64
Cap du marché
Clôture Veille
4,40
Ouverture
4,49
Dernière Transaction
500
@
4.41
Dernière heure de transaction
Volume financier
-
VWAP
-
Volume moyen (3 m)
31 778
Actions en circulation
27 282 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-4,26
Bénéfice par action (BPA)
-1,03
Chiffre d'affairess
-
Bénéfice net
-28,22M

À propos de Eupraxia Pharmaceuticals Inc

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Siège social
Victoria, British Columbia, Can
Fondé
-
Eupraxia Pharmaceuticals Inc est coté dans le secteur Pharmaceutical Preparations de la Toronto Stock Exchange avec le ticker EPRX. Le dernier cours de clôture d'Eupraxia Pharmaceuticals était de $4,40. Au cours de la dernière année, les actions de Eupraxia Pharmaceuticals ont été négociées dans une fourchette de prix de $ 3,07 à $ 7,64.

Eupraxia Pharmaceuticals compte actuellement 27 282 000 actions en circulation. La capitalisation boursière d'Eupraxia Pharmaceuticals est de $120,04 million. Eupraxia Pharmaceuticals a un ratio cours/bénéfice (ratio PE) de -4.26.

EPRX Dernières nouvelles

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months

Eupraxia's DiffuSphere™ Technology Demonstrates Targeted Drug Release while Minimizing Systemic Exposure for a Period of More Than Six Months PR Newswire VICTORIA, BC, Nov. 20, 2024...

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting

Eupraxia Pharmaceuticals to Present at American College of Rheumatology Convergence 2024 Annual Meeting PR Newswire VICTORIA, BC, Nov. 14, 2024 VICTORIA, BC, Nov. 14, 2024 /PRNewswire/ - Eupraxia...

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November 15, 2024

Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Eosinophilic Esophagitis: The Emerging Digestive Disorder Frequently Misdiagnosed", on November...

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis

Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis PR Newswire VICTORIA, BC, Nov. 12, 2024 One...

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results

Eupraxia Pharmaceuticals Reports Third Quarter 2024 Financial Results PR Newswire VICTORIA, BC, Nov. 7, 2024 VICTORIA, BC, Nov. 7, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc...

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million

Eupraxia Pharmaceuticals Announces that it has Closed a Non-Brokered Private Placement of C$44.5 Million PR Newswire VICTORIA, BC, Oct. 31, 2024 VICTORIA, BC, Oct. 31, 2024 /PRNewswire/...

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024

Eupraxia Pharmaceuticals to Present at American College of Gastroenterology Annual Scientific Meeting 2024 PR Newswire VICTORIA, BC, Oct. 28, 2024 VICTORIA, BC, Oct. 28, 2024 /PRNewswire/...

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis

Lancet Rheumatology Publishes Phase 2b Data on Eupraxia Pharmaceuticals' EP-104IAR for the Treatment of Knee Osteoarthritis PR Newswire VICTORIA, BC, Oct. 15, 2024 Publication...

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024

Eupraxia Pharmaceuticals to Present at United European Gastroenterology Week 2024 PR Newswire VICTORIA, BC, Oct. 10, 2024 VICTORIA, BC, Oct. 10, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc...

Eupraxia Pharmaceuticals Strengthens Senior Management Team

Eupraxia Pharmaceuticals Strengthens Senior Management Team PR Newswire VICTORIA, BC, Oct. 2, 2024 VICTORIA, BC, Oct. 2, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-0.39-8.1254.84.894.13141554.55977152CS
4-0.04-0.8988764044944.455.453.89275354.60846979CS
12129.32551319653.415.453.07317784.12373102CS
260.7119.18918918923.75.453.07235883.917439CS
52-2.05-31.733746136.467.643.07329984.33149843CS
1562.41120.529.10.8276504.25502016CS
260-3.34-43.09677419357.759.10.8252334.23533796CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
SMCSulliden Mining Capital Inc
$ 0,02
(33,33%)
5,05k
FLNTFlint Corporation
$ 0,025
(25,00%)
40,92k
CNTCentury Global Commodities Corporation
$ 0,03
(20,00%)
3k
APLIAppili Therapeutics Inc
$ 0,035
(16,67%)
401,3k
NCFNorthcliff Resources Ltd
$ 0,035
(16,67%)
1 000
CRWNCrown Capital Partners Inc
$ 1,40
(-24,73%)
4,61k
XTRAXtract One Technologies Inc
$ 0,53
(-19,70%)
352,94k
PPRPrairie Provident Resources Inc
$ 0,03
(-14,29%)
7,85k
PNPPinetree Capital Ltd
$ 11,88
(-13,35%)
55,5k
AVNTAvant Brands Inc
$ 0,53
(-13,11%)
12,55k
CNQCanadian Natural Resources Ltd
$ 45,65
(-2,12%)
19,21M
BITFBitfarms Ltd
$ 3,24
(9,83%)
11,15M
SUSuncor Energy Inc
$ 54,34
(-1,11%)
10,06M
TDToronto Dominion Bank
$ 73,53
(-0,66%)
9,31M
GWOGreat West Lifeco Inc
$ 48,76
(-0,23%)
7,15M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock